Back to Search
Start Over
Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia
- Source :
- Brøsen, J M B, Agesen, R M, Alibegovic, A C, Andersen, H U, Beck-Nielsen, H, Gustenhoff, P, Hansen, T K, Hedetoft, C G R, Jensen, T J, Stolberg, C R, Juhl, C B, Lerche, S S, Nørgaard, K, Parving, H-H, Tarnow, L, Thorsteinsson, B & Pedersen-Bjergaard, U 2022, ' Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia ', Diabetes Technology & Therapeutics, vol. 24, no. 9, pp. 643-654 . https://doi.org/10.1089/dia.2021.0567, Brøsen, J M B, Agesen, R M, Alibegovic, A C, Ullits Andersen, H, Beck-Nielsen, H, Gustenhoff, P, Krarup Hansen, T, Hedetoft, C G R, Jensen, T J, Stolberg, C R, Bogh Juhl, C, Lerche, S S, Nørgaard, K, Parving, H H, Tarnow, L, Thorsteinsson, B & Pedersen-Bjergaard, U 2022, ' Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia ', Diabetes Technology & Therapeutics, vol. 24, no. 9, pp. 643-654 . https://doi.org/10.1089/dia.2021.0567
- Publication Year :
- 2022
- Publisher :
- Mary Ann Liebert Inc, 2022.
-
Abstract
- Background and Aims: Nocturnal hypoglycemia is mainly a consequence of inappropriate basal insulin therapy in type 1 diabetes (T1D) and may compromise optimal glycemic control. Insulin degludec is associated with a lower risk of nocturnal hypoglycemia in T1D. As nocturnal hypoglycemia is often asymptomatic, we applied continuous glucose monitoring (CGM) to detect a more precise occurrence of nocturnal hypoglycemia in the HypoDeg trial, comparing insulin degludec with insulin glargine U100 in people with T1D and previous nocturnal severe hypoglycemia. Materials and Methods: In the HypoDeg trial, 149 people with T1D were included in an open-label randomized cross-over trial. Sixty-seven participants accepted optional participation in the predefined substudy of 4 × 6 days of blinded CGM requiring completion of at least one CGM period in each treatment arm. CGM data were reviewed for hypoglycemic events. Results: Treatment with insulin degludec resulted in a relative rate reduction (RRR) of 36% (95% confidence interval [CI]: 10%-54%; P
- Subjects :
- Blood Glucose
Glycated Hemoglobin
endocrine system diseases
Blood Glucose Self-Monitoring
Endocrinology, Diabetes and Metabolism
nutritional and metabolic diseases
Insulin Glargine
Hypoglycemia
Insulin, Long-Acting
Medical Laboratory Technology
Type 1 diabetes
Diabetes Mellitus, Type 1
Endocrinology
Insulin glargine U100
Nocturnal hypoglycemia
Humans
Hypoglycemic Agents
Insulin analogs
Insulin degludec
Subjects
Details
- ISSN :
- 15578593 and 15209156
- Volume :
- 24
- Database :
- OpenAIRE
- Journal :
- Diabetes Technology & Therapeutics
- Accession number :
- edsair.doi.dedup.....83477b07b58cfa9237757d8626ffbdc9